Clinical trial
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT02087085 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Lead sponsor
- Allergan
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 9, 2014
- Completion date
- March 30, 2018
- Enrollment
- 310 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.